How Psychedelics and Ketamine Are Changing the Landscape of Mental Health Treatment

The Spectrum of Psychedelics

Psychedelics encompass a diverse range of substances, including dissociatives like ketamine and empathogens such as MDMA. While all psychedelics induce altered states of consciousness, their mechanisms and effects vary significantly. Ketamine, for instance, creates a dissociative state and has proven effective for treating depression and chronic pain. In contrast, hallucinogens like psilocybin, LSD, and ayahuasca are known for profound psychological experiences and often trigger metaplasticity—a state in which the brain's capacity to learn and adapt is enhanced.

As a class of psychoactive substances, psychedelics profoundly affect perception, mood, and cognition. They can alter sensory experiences, heighten introspection, and foster a greater sense of awareness. Most psychedelics achieve these effects by interacting with serotonin receptors in the brain, particularly the 5-HT2A receptor, which plays a central role in their transformative impact.

Examples of Common Psychedelics:

• Classic Psychedelics: LSD (lysergic acid diethylamide), psilocybin (found in magic mushrooms), DMT (dimethyltryptamine), and mescaline.
• Dissociative Psychedelics: Ketamine and PCP, which produce a sense of detachment from the self or environment.
• Empathogens: Substances like MDMA, which enhance feelings of empathy and emotional connection.

Critical Periods: Reopening the Brain’s Learning Windows

Critical periods are unique windows during early development when the brain is particularly receptive to learning. These periods allow children to acquire language, motor skills, and other foundational abilities effortlessly. However, as we age, these windows close, making new learning more challenging.

Dr. Dölen’s research suggests that psychedelics, including ketamine, can temporarily reopen these critical periods in adults. For example, ketamine’s ability to induce a brief dissociative state correlates with a two-day reopening of critical periods. This phenomenon allows for therapeutic interventions like psychotherapy or physical therapy to be more effective.

The duration of reopened critical periods is thought to correlate with the length of the subjective effects of psychedelics, with longer-lasting substances like LSD and Ibogaine inducing the most prolonged periods of openness.

Ketamine’s Unique Role in Neuroplasticity

Ketamine’s rapid-acting nature and safety profile make it a standout psychedelic. Unlike traditional antidepressants that require weeks to take effect, ketamine can lift depressive symptoms within hours. This is partly due to its ability to boost glutamate, the brain’s primary excitatory neurotransmitter, enhancing synaptic plasticity.

In clinical settings, ketamine is used for:

1. Depression and PTSD: By reopening critical periods, ketamine facilitates the unlearning of negative thought patterns and supports the formation of healthier mental habits.
2. Chronic Pain: Ketamine disrupts pain signals and recalibrates the brain’s perception of pain.
3. Stroke Recovery: Emerging research highlights its potential to reopen critical periods for motor learning, enabling more effective rehabilitation.

As evidence of ketamine’s powerful potential for effectively treating depression, the FDA has, as of January 2025, approved a derivative of ketamine known as esketamine, marketed under the brand name SPRAVATO, as monotherapy for major depressive disorder. This marks a significant step forward for ketamine’s role in modern psychiatry, as previous approvals required patients to be classified as treatment-resistant—meaning they had failed trials of at least two different antidepressants.

Psychedelics Beyond Ketamine

While ketamine offers unique advantages, other psychedelics also show promise in specific contexts:

• Psilocybin and MDMA: These drugs reopen critical periods for up to two weeks, making them effective for conditions like PTSD and end-of-life anxiety. Their longer duration allows for extended therapeutic engagement.
• LSD: With effects lasting up to three weeks, LSD is being explored for its potential in facilitating enduring behavioral change.
• Ibogaine: Known for its long-lasting impact (up to four weeks or more), ibogaine is particularly effective for addressing entrenched issues like addiction.

Combining Psychedelics with Therapy

The synergy between psychedelics and therapy is thought to be key to their success. For instance, MDMA-assisted therapy helps PTSD patients by fostering trust and enabling emotional breakthroughs. Similarly, ketamine therapy combined with psychotherapy enhances emotional resilience and provides a framework for interpreting the psychedelic experience.

While psychedelics often have rapid-acting effects with symptom alleviation, the medicine itself does not provide guidance. A key aspect of ketamine-assisted therapy is the guidance provided by a trained therapist, helping patients integrate their psychedelic experience. This not only allows patients to gain valuable insights but, more importantly, empowers them to make actionable changes in their behaviors and lifestyle, leading to longer-lasting effects than the medicine alone can provide.

Future Directions and Caution

Although psychedelics hold great promise, their therapeutic potential is still being explored. Dr. Dölen’s lab is advancing clinical trials to determine how psychedelics can aid stroke recovery and other neurological conditions. However, she cautions against viewing psychedelics as a panacea. The success of these treatments often hinges on timing, dosage, and pairing with appropriate therapeutic modalities.

The resurgence of psychedelics in neuroscience represents a paradigm shift. Substances like ketamine are no longer confined to operating rooms but are redefining how we approach mental health and neurorehabilitation. As research unfolds, these drugs may transform our understanding of brain plasticity and offer hope to millions seeking healing and growth.

‍

About the Author

Dr. Ray Rivas, a former general and trauma surgeon with over a decade of experience utilizing ketamine, became a ketamine therapy specialist to treat mental health and pain after witnessing its profound impact on his hospital trauma patients and his own mental health. As the founder and medical director of Innerbloom Ketamine Therapy in San Luis Obispo, California, Dr. Rivas applies his extensive medical expertise to provide safe, evidence-based ketamine treatments for mood disorders, including depression, anxiety, PTSD, and chronic pain. His passion lies in helping patients find relief and rediscover hope through personalized, compassionate care.

‍

References:

"Are Psychedelics Good for the Brain? Dr. Gül Dölen is Using Octopuses to Find the Answers." Being Patient, www.beingpatient.com.

Carhart-Harris, Robin L., et al. "Psilocybin with Psychological Support for Treatment-Resistant Depression: Six-Month Follow-Up." Psychopharmacology, vol. 235, no. 2, 2018, pp. 399–408. DOI:10.1007/s00213-017-4771-x.

Dölen, Gül. "Study Shows Psychedelic Drugs Reopen Critical Periods for Social Learning." Hopkins Medicine, 2023, www.hopkinsmedicine.org/news.

"Esketamine (SPRAVATO) Approved as Monotherapy for Major Depressive Disorder." January 2025, www.healio.com.

López-Giménez, Juan F., and Javier González-Maeso. “Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways.” Current Topics in Behavioral Neurosciences, vol. 36, 2018, pp. 45–73. DOI:10.1007/7854_2017_478.

Nichols, David E., and Charles D. Nichols. "Psychedelics as Medicines: An Emerging New Paradigm." Clinical Pharmacology & Therapeutics, vol. 101, no. 2, 2017, pp. 209–219. DOI:10.1002/cpt.557.

"Psychedelics Can Reopen Periods of Heightened Brain Plasticity." BrainFacts, www.brainfacts.org.

Xiong, Zhongwei, et al. “Neuronal Brain Injury After Cerebral Ischemic Stroke Is Ameliorated After Subsequent Administration of (R)-Ketamine, but Not (S)-Ketamine.” Pharmacology, Biochemistry, and Behavior, vol. 191, 2020, p. 172904. DOI:10.1016/j.pbb.2020.172904.

Zhang, Yujing, et al. “(R,S)-Ketamine Promotes Striatal Neurogenesis and Sensorimotor Recovery Through Improving Poststroke Depression-Mediated Decrease in Atrial Natriuretic Peptide.” Biological Psychiatry: Global Open Science, vol. 1, no. 2, 2021, pp. 90–100. DOI:10.1016/j.bpsgos.2021.04.002.